Skip to main content

Table 5 Published studies of a dose-intense regimen of capecitabine and oxaliplatin

From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

Trial n Chemotherapy Relative dose intensity* Overall response (%) PFS (months) Gd 3/4 diarrhoea (%)
Ox Cape
This trial
_________   q2w Oxali 85 mg/m2      
  19   Cape 1750 mg/m2 BDd1-7 98% 131% 47.1% 6.9 31.6%
30   Cape 1500 mg/m2 BD d1-7 98% 113% 26.9% 8.9 23.3%
Bevac 5 mg/kg
Phase II trials
Scheithauer [11] 89 q2w Oxali 85 mg/m2 98% 131% 54.5% 10.5 9%
Cape 1750 mg/m2 BDd1-7
vs.
q3w Oxali 130 mg/m2    42.2% 6 12%
Cape 1000 mg/m2 BD d1-14
Fedele [19] 47** q2w Oxali 100 mg/m2 115% 75% 51% - 4.3%
Cape 1000 mg/m2BD d1-7
Yuan [20] 23** q2w Oxali 85 mg/m2 98% N/A 61% - 26%
Cape 2500 mg BD d1-7
Cetux 250 or 500 mg/m2
Lembersky [21]   q2w Oxali 85 mg/m2    38% 10 18%
11***   Cape 1250 mg/m2BDd1-7 98% 94%    
29   Cape 1500 mg/m2 BDd1-7 98% 113%
Bevac 5 mg/kg
Phase III trials
Hurwitz [17] 435 q2w Oxali 85 mg/m2 98% 113% 21.7% 8.4 29%
  Cape 1500 mg/m2 BD d1-7      
Bevac 5 mg/kg
vs.
   q3w Oxali 130 mg/m2    29.4% 9.7 24%
Cape 850 mg/m2 BD d1-7
Bevac 5 mg/kg
Tournigand [22] 200 q2w Oxali 100 mg/m2 115% 94% - - 21%
  Cape 1250 mg/m2BD d1-7    - -  
Bevac 5 mg/kg
vs.
q2w Oxali 100 mg/m2      5%
LV 400 mg/m2      
5FU 2400 mg/m2 ci 46 hrs
  Bevac 5 mg/kg  
  1. Oxali: Oxaliplatin; Cape: Capecitabine; Bevac: Bevacizumab; LV: leucovorin; 5FU: 5-fluorouracil.
  2. *Compared to standard CapeOx: oxaliplatin 130 mg/m2 on Day 1 and capecitabine 1000 mg/m2/BD D1-14.
  3. **Number eligible for toxicity analysis.
  4. ***Dose of capecitabine was increased in trial due to tolerability at low dose.